Blog

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid … – UroToday

Efficacy and safety of chimeric antigen receptor Tcell (CAR-T) therapy in patients with haematological and solid …
UroToday
Patients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CART) cells redirects a patient's immune cells against the tumour antigen. CART cell therapy has demonstrated promise in treating

2018-01-04 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.